 Connection
Robert Page to Hydroxymethylglutaryl-CoA Reductase Inhibitors
This is a "connection" page, showing publications Robert Page has written about Hydroxymethylglutaryl-CoA Reductase Inhibitors.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.718 |
|
|
|
-
Golightly LK, Barber GR, Barron MA, Page RL. Statins and daptomycin: safety assessment of concurrent use and evaluation of drug interaction liability. Drug Metabol Drug Interact. 2013; 28(1):49-58.
Score: 0.317
-
Newman CB, Preiss D, Tobert JA, Jacobson TA, Page RL, Goldstein LB, Chin C, Tannock LR, Miller M, Raghuveer G, Duell PB, Brinton EA, Pollak A, Braun LT, Welty FK. Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2019 02; 39(2):e38-e81.
Score: 0.121
-
Wiggins BS, Lamprecht DG, Page RL, Saseen JJ. Recommendations for Managing Drug-Drug Interactions with Statins and HIV Medications. Am J Cardiovasc Drugs. 2017 Oct; 17(5):375-389.
Score: 0.110
-
Wiggins BS, Saseen JJ, Page RL, Reed BN, Sneed K, Kostis JB, Lanfear D, Virani S, Morris PB. Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2016 11 22; 134(21):e468-e495.
Score: 0.103
-
Slejko JF, Page RL, Sullivan PW. Cost-effectiveness of statin therapy for vascular event prevention in adults with elevated C-reactive protein: implications of JUPITER. Curr Med Res Opin. 2010 Oct; 26(10):2485-97.
Score: 0.068
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|